The Priority Review

Tag

Alexion

1 story

  1. Clinical trials

    Alexion posts results of Phase 3 ARTEMIS ravulizumab trial

    The company posted results for its Phase 3 ARTEMIS study, which enrolled 555 participants and was terminated after primary completion on October 7, 2025. The trial assessed a single dose of ravulizumab IV versus placebo in adult participants with CKD undergoing non-emergent cardiac surgery with cardiopulmonary bypass.